The following are US data on the sponsorship of clinical trials involving 3TC, using data from the AIDS Clinical Trial Information Service (ACTIS). http://excalibur.actis.org/aidstrialG.html

The ACTIS database identifies 90 clinical trials involving 3TC, including trials that involve 3TC in combination with or comparison to other drugs. The ACTIS data permits us to identify the sponsors of 87 of those trials.

• 42 of these trials were sponsored by the federal government, and one was co-sponsored by NIAID and two private firms.
• Of the remaining 44 trials, one was sponsored by a University, and 43 we sponsored by private firms.

Note that this is not definitive regarding funding of the trials, because trials that were sponsored by private firms may have been funded (all or in part) by the federal government.

Moreover, any trials that quality for as an orphan indication (200,000 US patients for a particular indication) are eligible for a 50 percent US tax credit.

Here is the break down on sponsorship of clinical trials involving 3TC, based upon s search (10/11/99) of the AIDS Clinical Trial Information Service (ACTIS) database.

A search (10/08/99) of the AIDS Clinical Trial Information Service (ACTIS) database revealed the following information on clinical trials of ACTG involving 3TC:

Number of clinical trials sponsored:

NIAID 40

NCI 2

NIAID/Bristol-Myers Squibb/Glaxo Wellcome/ DuPont 1

Glaxo Wellcome 14

Merck 8

Hoffman and La Roche 5

Bristol-Myers Squibb 4

Pharmacia and Upjohn 3

Abbott 2

Gilead Sciences Inc. 2

Triangle 1

Boehringer Ingelheim 1

Dupont/Merck 2

Gilead Sciences Inc/ Bristol-Myers Squibb/ Glaxo Wellcome/DuPont 1

Cornell AIDS Clinical Trial Unit 1